Edison Investment Research has today published its initial analysis of Scandion Oncology.
With its global audience Edison will support the profiling of Scandion towards the international investment community.
You can find the analysis here: https://t.co/bZRy5j5ymB
#Scandion
We are excited to announce the appointment of Dr. Alfredo Zurlo as Chief Medical Officer (CMO) at Scandion Oncology. Alfredo joins immediately as part of the company’s Executive Management.
Read more: https://t.co/ir4cC9Tlej
#Scandion#SCOL#oncology#cancer
Our Annual General Meeting (AGM) will be held on Wednesday, April 27 at 4 PM CET in Copenhagen, Denmark.
3 new members of the Board of Directors are nominated for election at the AGM. Learn more at https://t.co/EdhTszIzj7
#Scandion#SCOL
Going forward we will be subject to research and analysis by Edison. With its global audience Edison will strongly support the profiling of Scandion and our mission to revert cancer drug resistance towards the international investment community.
https://t.co/TBczcgKKKU
#Scandion
Interested in hearing about @scandion's approach to treating #chemotherapy-resistant #cancers? Discover all you need to know from CEO Bo Rode Hansen. $SCOL #oncology
https://t.co/BAFZ6OoLpv
Read our QuickView on @Scandion Oncology ahead of Edison Open House: #Healthcare 2022, launching on 25 January.
Scandion Oncology is a #biotechnology company focused on the development of therapies to alleviate drug resistance in prevalent #cancers. $SCOL
https://t.co/eryOTvUtM8
We are happy to welcome Mads Kronborg acting as Head of External Communication as we look to further enhance our communication with our many external stakeholders.
https://t.co/NSKmzcoCvF
Det var tydligen dags för ledningen att handla igen i $Scol , COO 8k samt CMO 30k⭐️.
Bolaget kommer presentera en hel del i januari, både för potentiella partners och investerare
🔹Biotech Showcase, 10-12 jan
🔹Redeye - Fight Cancer event, 20 jan
🔹Edison Open House 25-27 Jan